Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
- Target Recruit Count
- 50
- Registration Number
- NCT02441816
- Locations
- 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 48
- Registration Number
- NCT02432547
- Locations
- 🇦🇺
Centre for Eye Research Australia, Melbourne, Victoria, Australia
🇦🇺Save Sight Institute, Sydney, New South Wales, Australia
Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Kamal Kishore, MD
- Target Recruit Count
- 6
- Registration Number
- NCT02403128
- Locations
- 🇺🇸
Illinois Retina and Eye Associates, Peoria, Illinois, United States
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02401945
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
- Conditions
- Interventions
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Ophthotech Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT02387957
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 117
- Registration Number
- NCT02384759
- Locations
- 🇫🇷
CHU Amiens - Hôpital Nord, Amiens CEDEX 1, France
🇫🇷ICO, Saint Herblain, France
🇫🇷CH, Perpignan, France
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2021-05-03
- Target Recruit Count
- 180
- Registration Number
- NCT02340949
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT02320474
- Locations
- 🇫🇷
Poitiers University Hospital, Poitiers, France
🇫🇷Polyclinic of POITIERS, Poitiers, France
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
- Conditions
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Greater Houston Retina Research
- Target Recruit Count
- 60
- Registration Number
- NCT02299336
- Locations
- 🇺🇸
Retina Consultants of Houston/The Medical Center, Houston, Texas, United States
🇺🇸Retina Consultants of Houston, The Woodlands, Texas, United States
🇺🇸Retina Consultants of Houston/Katy office, Katy, Texas, United States
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02298959
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.